PMID- 36105225
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220917
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Quantitative comparison of the efficacies and safety profiles of three first-line 
      non-platinum chemotherapy regimens for advanced non-small cell lung cancer.
PG  - 806728
LID - 10.3389/fphar.2022.806728 [doi]
LID - 806728
AB  - Objectives: The purpose of this study was to quantify the efficacies and safety 
      profiles of the three first-line non-platinum chemotherapy regimens recommended 
      in the National Comprehensive Cancer Network guidelines. Materials and Methods: 
      The PubMed and Cochrane Library databases were searched comprehensively, and 
      clinical trials involving patients with advanced non-small cell lung cancer 
      treated with one of three first-line non-platinum regimens (gemcitabine combined 
      with vinorelbine, gemcitabine combined with docetaxel, or gemcitabine alone) were 
      included in the analysis. A parametric proportional hazard survival model was 
      established to analyze the time course of overall survival (OS). The objective 
      response rate (ORR) and incidence rates of grade 3-4 adverse events (AEs) were 
      summarized using a single-arm meta-analysis with a random-effects model. Results: 
      Seventeen studies met the inclusion criteria. Age and performance status (PS) 
      scores were significant predictors of OS. For each 10-years increase in age, 
      mortality risk increased by 18.5%, and the mortality risk increased by 4% for 
      every 10% increase in the proportion of patients with a PS score of 2. After 
      correcting for the above factors, we found that the three first-line non-platinum 
      chemotherapy regimens did not differ based on OS or toxicity. Conclusion: There 
      was no significant difference in OS or toxicity among the three first-line 
      non-platinum chemotherapy regimens. Age and PS scores were significant predictors 
      of OS, and their heterogeneity across different studies should be considered in 
      cross-study comparisons and sample size estimations when designing clinical 
      trials.
CI  - Copyright (c) 2022 Yang, Zhu, Liu, Zheng and Li.
FAU - Yang, Qian-Yu
AU  - Yang QY
AD  - Center for Drug Clinical Research, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Zhu, Lin
AU  - Zhu L
AD  - Center for Drug Clinical Research, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Liu, Hong-Xia
AU  - Liu HX
AD  - Center for Drug Clinical Research, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Zheng, Qing-Shan
AU  - Zheng QS
AD  - Center for Drug Clinical Research, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Li, Lu-Jin
AU  - Li LJ
AD  - Center for Drug Clinical Research, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220829
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9465165
OTO - NOTNLM
OT  - NSCLC
OT  - ORR
OT  - OS
OT  - influencing factors
OT  - non-platinum chemotherapy
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/16 06:00
MHDA- 2022/09/16 06:01
PMCR- 2022/08/29
CRDT- 2022/09/15 02:17
PHST- 2021/11/01 00:00 [received]
PHST- 2022/08/01 00:00 [accepted]
PHST- 2022/09/15 02:17 [entrez]
PHST- 2022/09/16 06:00 [pubmed]
PHST- 2022/09/16 06:01 [medline]
PHST- 2022/08/29 00:00 [pmc-release]
AID - 806728 [pii]
AID - 10.3389/fphar.2022.806728 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Aug 29;13:806728. doi: 10.3389/fphar.2022.806728. 
      eCollection 2022.